Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
BIOCON On Other Exchanges
Symbol
Exchange
BIOCON is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

biocon ltd (BIOCON) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCON LTD (BIOCON)

Related News

No related news articles were found.

biocon ltd (BIOCON) Related Businessweek News

No Related Businessweek News Found

biocon ltd (BIOCON) Details

Biocon Limited develops and sells biotechnology products for the pharmaceutical sector in India and internationally. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, opthalmics, peptides, oral anti-diabetic agents, anti-inflammatory agents, hepatoprotective agents, and probiotics; and biosimilars comprising human insulin, insulin glargine, insulin lispro, insulin aspart, erythropoietin, filgrastim, streptokinase, and monoclonal antibodies. The company also provides branded formulations in the areas of diabetology, oncotherapeutic, nephrology, cardiology, immunotherapy, comprehensive care and bioproducts; and out-licensing services. In addition, it offers contract manufacturing services, including mammalian cell culture fermentation, microbial cell culture fermentation, and synthetic chemistry to small-to-medium sized pharmaceutical and biotech companies; undertakes clinical research activities on discovering new biomarkers; and provides integrated contract research services to support discovery and development, for small and large molecules. The company was founded in 1978 and is headquartered in Bengaluru, India.

Founded in 1978

biocon ltd (BIOCON) Top Compensated Officers

Founder, Chairman, Managing Director, Member ...
Total Annual Compensation: 14.1M
Compensation as of Fiscal Year 2014.

biocon ltd (BIOCON) Key Developments

Biocon Limited Reports Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015; Provides Capex Guidance for the Next Five Years; Provides Tax Rate Guidance for the Year 2015

Biocon Limited reported audited consolidated earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 8,303.8 million against INR 7,225.9 million for the same period a year ago. Total income from operations (net) was INR 8,376.8 million against INR 7,285.3 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,267.1 million against INR 1,215.5 million for the same period a year ago. Profit from ordinary activities before tax was INR 2,486.0 million against INR 1,380.6 million for the same period a year ago. Net profit was INR 2,168.0 million against INR 1,189.1 million for the same period a year ago. Earnings per diluted share (not annualized) were INR 10.08 against INR 5.69 for the same period a year ago. Total revenue was INR 8,540 million against INR 7,460 million for the same period a year ago. EBITDA was INR 2,020 million against INR 1,930 million for the same period a year ago. The drop in EBITDA is largely due to increased R&D spends both in fourth quarter as well as the full year. For the year, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 30,599.7 million against INR 28,527.2 million for the same period a year ago. Total income from operations (net) was INR 30,898.1 million against INR 28,773.1 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 4,748.9 million against INR 4,834.9 million for the same period a year ago. Profit from ordinary activities before tax was INR 6,241.3 million against INR 5,376.6 million for the same period a year ago. Net profit was INR 5,284.7 million against INR 4,307.5 million for the same period a year ago. Earnings per diluted share (not annualized) were INR 24.87 against INR 20.82 for the same period a year ago. Total revenue was INR 31,430 million against INR 29,330 million for the same period a year ago. EBITDA was INR 7,490 million against INR 7,430 million for the same period a year ago. Full year, adjusted net profit was INR 4,020 million. For the quarter, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 5,604.7 million against INR 5,375.7 million for the same period a year ago. Total income from operations (net) was INR 5,833.8 million against INR 5,714.3 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 703.6 million against INR 882.4 million for the same period a year ago. Profit from ordinary activities before tax was INR 623.3 million against INR 990.9 million for the same period a year ago. Net profit was INR 477.9 million against INR 867.4 million for the same period a year ago. Earnings per diluted share (after giving impact of scheme of merger for earlier year) were INR 2.39 against INR 4.37 for the same period a year ago. For the year, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 21,417.9 million against INR 20,980.7 million for the same period a year ago. Total income from operations (net) was INR 22,416.0 million against INR 22,025.0 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 3,018.5 million against INR 3,488.2 million for the same period a year ago. Profit from ordinary activities before tax was INR 4,282.8 million against INR 4,085.1 million for the same period a year ago. Net profit was INR 3,612.2 million against INR 3,243.1 million for the same period a year ago. Earnings per diluted share (after giving impact of scheme of merger for earlier year) were INR 18.06 against INR 16.62 for the same period a year ago. For the next five years, the company to invest in couple of greenfield projects. Apart from that, the company's capex, which the company call maintenance capex, would be around INR 2,000 million to INR 2,500 million per year. For the fiscal year 2016, the company expects tax rate to be 20% to 22%.

Biocon Limited Receives Approval for Insulin Glargine through its Partner PISA Farmaceutica

Biocon Limited announced that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PISA Farmaceutica (PISA).

Biocon Limited, Board Meeting, Apr 29, 2015

Biocon Limited, Board Meeting, Apr 29, 2015. Agenda: To approve and take on record the audited financial results for the year ended on March 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOS:IN 445.80 INR -8.10

BIOCON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cambrex Corp $38.14 USD +0.86
Depomed Inc $23.89 USD +0.03
Divi's Laboratories Ltd 1,758 INR -25.45
Flamel Technologies SA $15.07 USD +0.73
Piramal Enterprises Ltd 987.00 INR +43.00
View Industry Companies
 

Industry Analysis

BIOCON

Industry Average

Valuation BIOCON Industry Range
Price/Earnings 17.8x
Price/Sales 2.9x
Price/Book 2.7x
Price/Cash Flow 12.4x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCON LTD, please visit www.biocon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.